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Parkinson's disease (PD) is caused by dopaminergic cell death in the substantia nigra, leading to a
reduced level of dopamine in the striatum. Oxidative stress is one of the causes of PD. Since symptomatic
PD therapies are used, identiﬁcation of compounds or proteins that inhibit oxidative stress-induced
neuronal cell death is necessary. DJ-1 is a causative gene product of familial PD and plays a role in
anti-oxidative stress reaction. We have identiﬁed various DJ-1-binding compounds, including
compound-23, that restored neuronal cell death and locomotion defects observed in neurotoxin-induced
PD models. In this study, wild-type and DJ-1-knockout mice were injected intraperitoneally with 1 mg/
kg of compound-23 and then with 30 mg/kg of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) at
1 h after injection. Five days after administration, the effects of compound-23 on MPTP-induced loco-
motion deﬁcits, on dopaminergic cell death and on brain dopamine levels were analyzed by rotor rod
tests, by staining cells with an anti-TH antibody and by an HPLC, respectively. The results showed that
compound-23 inhibited MPTP-induced reduction of retention time on the rotor rod bar, neuronal cell
death in the substantia nigra and striatum and dopamine content in wild-type mice but not in DJ-1-
knockout mice, indicating a DJ-1-dependent effect of compound-23.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Parkinson's disease (PD) is a chronic neurodegenerative disease
caused by dopaminergic cell death, and genetic and environmental
factors are thought to affect the onset of PD. Onset of PD is thought
be induced, to some degree, by oxidative stress, but the precise
mechanisms are still not known. Although a precursor of dopa-
mine, inhibitors of dopamine degradation and dopamine releasers
have been used for PD therapy, cell death progresses during
treatment. Identiﬁcation of compounds or proteins that inhibit
oxidative stress-induced neuronal cell death is necessary.þ81 11 706 4988.
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rmacological Society.
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d/4.0/).DJ-1 was ﬁrst identiﬁed by our group as a novel oncogene
product (1) and later found to be a causative gene product of a
familial form of PD, PARK7 (2). DJ-1 plays various roles, including
transcriptional regulation (3e9) and anti-oxidative stress reaction
(10e13), and loss of its function is thought to result in the onset of
PD. DJ-1 has three cysteines at amino acid numbers 46, 53, and 106
(C46, C53, and C106, respectively). Although oxidation of C106 is
necessary for DJ-1 to exert its activity (12e15), excessive oxidation
of C106 is thought to render DJ-1 inactive (16,17), and such oxidized
DJ-1 has been observed in patients with the sporadic form of PD
and Alzheimer disease (18,19).
We have shown that administration of DJ-1 protein dramatically
reduced dopaminergic cell death and inhibited locomotion deﬁcit
in a PD model in rats where 6-hydroxydopamine (6-OHDA) had
been injected (20), suggesting that DJ-1 is a pharmaceutical target
for PD. Furthermore, we identiﬁed compounds that bind to thenese Pharmacological Society. This is an open access article under the CC BY-NC-ND
K. Takahashi-Niki et al. / Journal of Pharmacological Sciences 127 (2015) 305e310306C106 region of DJ-1 and prevent excessive oxidation of C106 of DJ-1,
and these compounds including compounds A and B, like DJ-1
protein, prevented oxidative stress-induced dopaminergic cell
death and restored locomotion deﬁcit in a PD model in rats
(21e23). These compounds were found by screening the University
Compound library, which contains approximately 30,000 com-
pounds. We further screened DJ-1-binding compounds from the
Zinc compound library that contains approximately 2,500,000
compounds. Of the compounds identiﬁed, N-[4-(8-methyl(4-
hydroimidazo[1,2-a]pyridin-2-yl))phenyl](3,4,5-
trimethoxyphenyl)carboxamide, which is DJ-1-binding compound-
23 (comp-23) (Fig. 1A), protected oxidative stress-induced cell
death both in cultured cells and in PD models in rats and mice, andA
B C
D
Fig. 1. Effect of compound-23 on MPTP-induced decrease in locomotion behavior of mice. A.
i.p. with various doses of compound-23. One hr after injection, mice were injected with 30
rotor-rod tests of mice were carried out at 5 days after ﬁrst injection (B). Mouse weight was a
were injected with compound-23 and MPTP as described in the legend for Fig. 1B and C, and
Non-signiﬁcant.the protective activity of comp-23 seemed to be stronger than that
of compound B (24). Speciﬁcity of compound-23 toward DJ-1 was
suggested by experiments using DJ-1-knockdown cells (24).
In this study, to further examine the speciﬁcity of compound-23
toward DJ-1, wild-type and DJ-1-knockout mice were injected with
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a neuro-
toxin that inhibits activity of mitochondrial complex I, in the
presence or absence of compound-23, and then the effects of
compound-23 on a locomotion deﬁcit, dopaminergic cell death and
dopamine levels in the striatum and substantia nigra of DJ-1-
knockout mice were examined. The results showed that while
MPTP-induced deﬁcit in wild-type mice were restored by admin-
istration of compound-23, DJ-1-knockout mice showed little effect,Chemical structure of compound-23. B and C. DJ-1(þ/þ) C57BL/6 mice were injected by
mg/kg MPTP. This combination of injection was carried out every day for 4 days, and
lso measured (C). The number of experiments (n) is 5. D. DJ-1(þ/þ) and DJ-1(/) mice
rotor-rod tests of mice were carried out. n is 7. Signiﬁcance: *p < 0.05, **p < 0.01. N.S.:
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phenotypes.
2. Materials and methods
2.1. Ethic statement
All animal experiments were carried out in accordance with the
National Institutes of Health Guide for the Care and Use of Labo-
ratory Animals, and the protocols were approved by the Committee
for Animal Research at Hokkaido University (the permit number
08-0468).
2.2. Mice and reagents
Originally established DJ-1-knockout mice were back-crossed
more than 15 times until their genotype was C57BL/6 background
(25). C57BL/6 mice purchased from Nippon SLC were used as con-
trol mice (i.e. with DJ-1(þ/þ)), and all of the mice were fed with
normal diet (Labo MR Stock, Nosan Corporation Life-Tech Depart-
ment, Yokohama, Japan) and housed under standard laboratory
conditions. Compound-23 was synthesized as described previously
(24) and dissolved in 1% dimethyl sulfoxide (DMSO, as a solvent forA
B
Fig. 2. Effect of compound-23 on MPTP-induced dopaminergic cell death in the substantia
described in the legend for Fig. 1B and C. Tissue sections of the substantia nigra were then p
ABC-staining (A) and counted by measuring their intensity (B) as described in Materials ancompound-23). MPTP, DMSO and other reagents were purchased
from Wako Pure Chemicals (Kyoto, Japan).
2.3. Administration of MPTP into mice
In experiment-1 (dopaminergic cell death) and experiment-2
(dopamine content), wild-type male C57BL/6 mice at 8, 11e12
and 9e12 weeks of age, respectively, and DJ-1-knockout male mice
at 11e13 weeks of age were used. Wild-type mice were ﬁrst
habituated to their mouse cage for three days after purchase from
the breeder. Compound-23 and 1% DMSO in saline as a negative
control were injected intraperitoneally (i.p.) into mice. One hr after
injection of compound-23, MPTP or saline (as the negative control)
was injected intraperitoneally into mice. The same combination of
the injection of compound-23 and MPTP was carried out every day
for four days, and then rotor rod tests were carried out at ﬁve days
after ﬁrst injection.
2.4. Rota-rod test
The rotor-rod treadmill (rotor rod SN-445, Shinano, Tokyo,
Japan) consists of a plastic rod, 6-cm in diameter and 36-cm long,
with a non-slippery surface 20-cm above the base (trip plate). Thisnigra. DJ-1(þ/þ) and DJ-1(/) mice were injected with compound-23 and MPTP as
repared and reacted with an anti-TH antibody. The TH-positive cells were visualized by
d methods. n is 7e8. Signiﬁcance: *p < 0.05, **p < 0.01. N.S.: Non-signiﬁcant.
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diameter), which enables ﬁve mice to walk on the rod at the same
time. In the present study, 10 speeds of the rotor mode were used:
5 r.p.m. for 5 min on ﬁrst day and 10 r.p.m. for 5 min on second and
third days for 5 min in a habituation period and 10 r.p.m. for 5 min
in experiments using MPTP-administered mice. The performance
time for remaining running on the rod was recorded for each of the
mice. Three tests per mouse were done and their average time was
used in further analyses.
2.5. Tissue preparation and immunohistochemistry
After assays assessing rotor rod performance, MPTP-treated
mice were perfused through the aorta with 30 ml of 10 mM PBS,A
B
Fig. 3. Effect of compound-23 on MPTP-induced dopaminergic cell death in the striatum o
described in the legend for Fig. 1B and C. Tissue sections of the striatum were then prepare
staining (A) and counted by measuring their intensity (B) as described in Materials and mefollowed by 30 ml of a cold ﬁxative consisting of 4% para-
formaldehyde in 100 mM phosphate buffer (PB) under deep anes-
thesia with pentobarbital (100 mg/kg, i.p.). After perfusion, the
brain was quickly removed, postﬁxed for one day with para-
formaldehyde in 100 mM PB and then incubated in 10%, 20% and
then 30% sucrose solutions in PBS at 4 C for one day each. The brain
was cut into 60-mm-thick slices in a cryostat and collected in PBS
containing 0.3% Triton X-100 (PBS-T). The striatal sections and
twenty-four sections of the substantia nigra were prepared from
sites at 2 mm in front of bregma.
Slices were ﬁrst incubated with 1.5% normal serum for 30 min
and reacted with an anti-tyrosine hydroxylase (TH) antibody (1/
8000 dilution, Millipore, Billerica, MA, USA) for 3 days at 4 C. TH-
positive cells were then incubated with a biotin-labeled secondaryf mice. DJ-1(þ/þ) and DJ-1(/) mice were injected with compound-23 and MPTP as
d and reacted with an anti-TH antibody. The TH-positive cells were visualized by ABC-
thods. n is 5. Signiﬁcance: *p < 0.05, **p < 0.01. N.S.: Non-signiﬁcant.
Fig. 4. Effect of compound-23 on MPTP-induced dopamine loss in the striatum. DJ-
1(þ/þ) and DJ-1(/) mice were injected with compound-23 and MPTP as
described in the legend for Fig. 1B and C. Dopamine content in the striatum was then
measured by using an HPLC as described in Materials and methods. n is 7. Signiﬁcance:
*p < 0.05, ***p < 0.001. N.S.: Non-signiﬁcant.
K. Takahashi-Niki et al. / Journal of Pharmacological Sciences 127 (2015) 305e310 309antibody for 120 min and visualized by incubation with ABC re-
agents (ABC kit, Vecstain, Southﬁeld, MI, USA) for 60 min followed
by DAB staining (SigmaFast, Sigma Coatings, Alexander, AR, USA).
2.6. Measurement of immunoreactive neurons and areas
The number of TH-immunopositive neurons in the substantia
nigra was calculated using Stereo Investigator (MBF Bioscience,
Williston, VT, USA). To measure the number and area of TH-
immunopositive neurons in the striatum, immunostained sec-
tions were photographed using a digital camera (E-330, OLYMPUS,
Tokyo, Japan) and their intensity was measured by ImageJ.
2.7. Measurement of dopamine content
DJ-1(þ/þ) and DJ-1(/) mice were treated with compound-23
and MPTP and then rotor-rod tests were carried out as described
above. Brains were cut out and sectioned using a brain slicer (MB-
A1-C, Muromachi Kikai, Tokyo, Japan), and the striatum in slices
was frozen at 70 C. The refrozen striatum in 20-volume/striatal
weight of a buffer containing 0.1 M perchloric acid was homoge-
nized and centrifuged at 15,000 rpm for 15 min at 4 C. Its super-
natant was ﬁltrated through 0.2 mmpore size ﬁlter and applied onto
a column with 250 mm  4.6 mm dimensions (TSK-GEL ODS-80Ts,
Tokyo Kaken, Tokyo, Japan). Dopamine was eluted with a buffer
containing 16:84 ratio of acetonitrile and 100mM phosphate buffer
(pH 3.9) and 300 mg/ml octanesulfonate at a ﬂow rate of 0.8 ml/
min and detected by absorbance at 230 nm.
2.8. Data analysis
Data are expressed as means ± S.E for mouse experiments.
Statistical analyses were performed using analysis of variance (one-
way ANOVA) followed by unpaired Student's t-test. For comparison
of multiple samples, the Aspin-Welch's t-test was used.
3. Results
3.1. Effect of compound-23 on MPTP-induced locomotion behavior
of mice
Chemical structure of DJ-1-binding compound-23 was
described in Fig. 1A. DJ-1(þ/þ) mice at 8,11e12 of agewere injected
by i.p. with various amounts of compound-23 andwith 1% DMSO in
saline as a vehicle control. One hr after injection, micewere injected
with 30 mg/kg MPTP. This combination of injection was carried out
every day for 4 days and rotor-rod tests of mice were carried out at
5 days after ﬁrst injection. As shown in Fig. 1B, MPTP treatment
decreased the retention time of mice on the bar to 40% of that
without MPTP treatment, and injection of compound-23 restored
the retention time in a dose-dependent manner up to the 1 mg/kg
dose. Body weight of mice was not affected by injection of
compound-23 and MPTP (Fig. 1C). We therefore used 1 mg/kg of
compound-23 for further studies.
3.2. Effect of compound-23 on MPTP-induced locomotion behavior
of DJ-1-knockout mice
DJ-1(þ/þ) and DJ-1(/) mice at 8, 11e12 and 11e13 weeks,
respectively, of age were injected by i.p. with compound-23 and
MPTP as described above, and rotor-rod tests were carried out. As
shown in Fig. 1D, MPTP attenuated retention activity of both DJ-
1(þ/þ) and DJ-1 (/) mice, and the effect of MPTP on retention
activity of DJ-1 (/) mice tended to be stronger than that of on
retention activity of DJ-1 (þ/þ) mice as described previously (26).While injection of compound-23 into DJ-1 (þ/þ) mice signiﬁcantly
restored attenuated retention activity, there was no effect of
compound-23 in DJ-1 (/) mice, indicating that pharmacological
activity of compound-23 depends on the presence of DJ-1.3.3. Effect of compound-23 on MPTP-induced dopaminergic cell
death in the substantia nigra and striatum of mice
The substantia nigra and striatum were cut out from DJ-1(þ/þ)
and DJ-1(/) mice that had been injected with compound-23 and
MPTP as described above. Tissue sections of the substantia nigra
and striatum were then prepared and reacted with an anti-TH
antibody. The TH-positive cells were visualized by ABC-staining
and counted by measuring their intensity. The results showed
that numbers of TH-positive neuron in the substantia nigra and
striatum were decreased by MPTP treatment and that injection of
compound-23 signiﬁcantly inhibited this reduction of TH-positive
neurons in DJ-1(þ/þ) mice but not in DJ-1(/) mice (Figs. 2 and
3, respectively). These results indicate that the pharmacological
activity of compound-23 depends on the presence of DJ-1.3.4. Effect of compound-23 on MPTP-induced dopamine loss in the
striatum
The effect of compound-23 and MPTP on dopamine content in
the striatum was then examined. DJ-1(þ/þ) and DJ-1(/) mice
were treated with compound-23 andMPTP as described above, and
rotor-rod tests were ﬁrst examined to conﬁrm that the experi-
mental system was working. Compound-23 signiﬁcantly restored
MPTP-induced reduction of rotor rod performance of DJ-1(þ/þ)
mice, but not that of DJ-1 (/) mice (data not shown). Dopa-
mine content in the striatumwas then measured by using an HPLC.
MPTP treatment decreased dopamine content in both DJ-1(þ/þ)
and DJ-1(/) mice, and the effect of MPTP on dopamine con-
tents in DJ-1(/) mice was greater than that in DJ-1(þ/þ) mice
(Fig. 4). While reduced dopamine content in DJ-1(þ/þ) was
K. Takahashi-Niki et al. / Journal of Pharmacological Sciences 127 (2015) 305e310310signiﬁcantly increased by injection of compound-23, dopamine
content in DJ-1(/) mice was not changed after injection of
compound-23, indicating again that pharmacological activity of
compound-23 depends on the presence of DJ-1.
4. Discussion
In this study, we examined the effect of compound-23 on a
MPTP-compromised dopamine system using DJ-1-knockout mice.
Points we analyzed are MPTP-induced locomotion defect, dopa-
minergic neuronal cell death and dopamine content in the striatum
and substantia nigra. To do so, DJ-1(þ/þ) and DJ-1(/) mice were
ﬁrst injected by i.p. with 1 mg/kg compound-23 and then with
30 mg/kg MPTP at 1 h after compound-23 injection. The results
showed that injection of compound-23 signiﬁcantly restored
MPTP-induced locomotion, dopaminergic neuronal cell death and
dopamine content in DJ-1(þ/þ) mice but not in DJ-1(/) mice,
indicating the DJ-1-dependent effect of compound-23. In a present
study, the injection of 30 mg/kg MPTP into mice did not show se-
vere damage. When we used much higher concentrations of MPTP,
almost all of the mice died (in past experiments: data not shown).
Even this concentration of MPTP, however, tended to affect DJ-1(/
) mice more severely than DJ-1(þ/þ) mice in terms of retention
time on the rotor-rod, number of dopaminergic cell loss and
dopamine content in areas of the brain known to be affected in PD.
These results were consistent with those published in another
report using another line of DJ-1-knockout mice (26). As previously
described in our manuscripts, DJ-1-binding compounds, including
compound-B (21) and compound-23 (24), did not show any effect
on 6-OHDA and rotenone-induced death of DJ-1-knockdown
neuronal cells, suggesting the DJ-1-dependency of DJ-1-binding
compounds. The results in this study validated this point in an
animal model of Parkinson's disease.
Since compound-23 was injected by i.p. into mice and since the
protective effect of compound-23 was observed in mice, these re-
sults also suggest that compound-23 penetrated through the blood
brain barrier (BBB) to show the pharmacological activity against an
MPTP-induced Parkinson's disease model. Although it is not known
howmuch of compound-23 passes through the BBB, it is promising
that modiﬁcation of the structure, side chains for instance, of
compound-23 improves penetration efﬁciency of compound-23
into the BBB, leading to creation of more effective compounds.
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